Investment case
GSK plc
GSK · 11 developments mapped · last assessed 2026-09-28
Market Ontology has mapped 11 macro, policy, and market developments to GSK plc since 2026-09-02. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for GSK yet, so no modelled value is shown. The GSK valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run GSK on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
HUTCHMED and GSK Initiate Global Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830
Strategic partnership validation and pipeline diversification. While early-stage, it represents a potential future revenue stream.
· Moves future revenue potential from partnered drugs, diversification of pipeline risk, long term growth prospects
- Open question
GSK Specialty Medicines Grow 14% as Company Prepares 20 Phase III Starts Ahead of Patent Cliff
Direct impact on future revenue streams and R&D expenses; market perception of pipeline strength vs. patent cliff risk.
· Moves future revenue growth rate, r&d intensity, probability of success for pipeline assets
What changed, by assumption
- 2026-09-11GSK Specialty Medicines Grow 14% as Company Prepares 20 Phase III Starts Ahead of Patent Cliff
- 2026-09-11GSK Specialty Medicines Grow 14% in H1 2026 Ahead of 2028 HIV Patent Cliff
- 2026-09-28HUTCHMED and GSK Initiate Global Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830
- 2026-09-02Gilead secures FDA approval for Bixlenvo, raises 2026 HIV sales outlook to 9-10%
- 2026-09-09Pfizer Beats Q2 Estimates at $15B Revenue and Raises Full-Year Guidance
- 2026-09-28HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830
- 2026-09-28HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-06-25 | Net debt | Bearish | Liability-management transactions often reduce gross debt or push maturities out. | 0.70 |
| 2026-06-25 | Interest expense | Bearish | Tender/exchange extends maturity profile and typically lowers near-term interest expense. | 0.70 |
| 2026-06-24 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-06-24 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-06-24 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-28 | HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 | Bullish | 1-5y | 0.30 |
| 2026-09-28 | HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830 | Bullish | 3-12m | 0.30 |
| 2026-09-28 | HUTCHMED doses first patient in global Phase Ia trial of KRAS-EGFR conjugate | Bullish | 3-12m | 0.30 |
| 2026-09-28 | HUTCHMED and GSK Initiate Global Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830 | Bullish | 1-3m | 0.40 |
| 2026-09-28 | HUTCHMED and GSK Initiate Phase Ia Trial for KRAS-EGFR Conjugate Therapy | Bullish | 1-5y | 0.30 |
| 2026-09-28 | HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR Conjugate | Bullish | 3-12m | 0.30 |
| 2026-09-11 | GSK Specialty Medicines Grow 14% as Company Prepares 20 Phase III Starts Ahead of Patent Cliff | mixed | 1-5y | 0.70 |
| 2026-09-11 | GSK Specialty Medicines Grow 14% in H1 2026 Ahead of 2028 HIV Patent Cliff | mixed | 3-12m | 0.70 |
| 2026-09-09 | Pfizer Beats Q2 Estimates at $15B Revenue and Raises Full-Year Guidance | watch | 1-3m | 0.30 |
| 2026-09-02 | Gilead secures FDA approval for Bixlenvo, raises 2026 HIV sales outlook to 9-10% | mixed | 3-12m | 0.40 |
| 2026-09-02 | FDA approves Gilead's Bixlenvo as HIV franchise sales outlook raised to 9-10% | mixed | 3-12m | 0.30 |